Glypressine

Glypressine is a prescription injectable solution that contains the vasopressin analog terlipressin as its active ingredient. Marketed in the European Union, this medication is supplied as an intravenous preparation, though strength information is not disclosed. Glypressine belongs to the vasoconstrictor therapeutic class and acts as a selective V1‑receptor agonist to increase vascular tone and lower portal pressure. It is administered under medical supervision for conditions needing rapid portal pressure reduction.

Glypressine is indicated for several serious clinical situations where vasoconstriction can improve outcomes.

- Management of hepatorenal syndrome in patients with advanced liver disease. - Control of acute variceal bleeding associated with portal hypertension. - Adjunctive therapy for septic shock when conventional vasopressors are insufficient. - Off‑label use in selected cases of refractory hypotension under specialist guidance.

The safety profile of Glypressine reflects its potent vasoconstrictive activity, with side effects ranging from mild to severe.

Common: - Headache or facial flushing. - Nausea, vomiting, or abdominal discomfort. - Transient hypertension or increase in blood pressure. - Peripheral edema or swelling of extremities.

Serious: - Severe hypertension leading to hypertensive crisis. - Cardiac arrhythmias or myocardial ischemia. - Ischemic complications such as digital necrosis. - Acute renal impairment or worsening kidney function.

Because Glypressine produces marked vasoconstriction, careful patient selection and monitoring are essential before and during therapy.

- Assess cardiovascular status, especially history of ischemic heart disease. - Monitor blood pressure frequently to detect excessive rises. - Evaluate renal function and fluid balance prior to infusion. - Use caution in patients with active gastrointestinal bleeding. - Avoid in uncontrolled hypertension or severe aortic stenosis. - Consider pregnancy status; safety data are limited.

Glypressine can interact with other agents that affect vascular tone or renal perfusion, requiring attention to concurrent medications.

Avoid: - Concurrent use of other potent vasopressors (e.g., norepinephrine, phenylephrine) that may cause extreme hypertension. - Combination with vasodilators such as nitroglycerin or hydralazine, which can blunt therapeutic effect.

Use with caution: - Diuretics that may exacerbate intravascular volume depletion. - ACE inhibitors or ARBs that influence renal hemodynamics. - Beta‑blockers, which may mask tachycardia response.